Craig S. Gibbs
Chief Executive Officer at Asher Biotherapeutics, Inc.
Net worth: - $ as of 2024-04-29
Craig S. Gibbs active positions
| Companies | Position | Start | End |
|---|---|---|---|
Asher Biotherapeutics, Inc.
 Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 2020-08-31 | - |
Career history of Craig S. Gibbs
Former positions of Craig S. Gibbs
| Companies | Position | Start | End |
|---|---|---|---|
| ARIDIS PHARMACEUTICALS, INC. | Director/Board Member | 2015-04-08 | 2023-03-26 |
| Independent Dir/Board Member | 2015-04-08 | 2023-03-26 | |
| FORTY SEVEN, INC. | Corporate Officer/Principal | 2015-08-31 | 2020-06-30 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director/Board Member | 2014-06-22 | 2016-08-31 |
| Independent Dir/Board Member | 2014-06-22 | 2016-08-31 | |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 1991-12-31 | 2012-12-31 |
Training of Craig S. Gibbs
| Massey University | Undergraduate Degree |
| University of Glasgow | Doctorate Degree |
| Golden Gate University | Masters Business Admin |
Statistics
International
| United States | 7 |
| New Zealand | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ARIDIS PHARMACEUTICALS, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Asher Biotherapeutics, Inc.
Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Commercial Services |
- Stock Market
- Insiders
- Craig S. Gibbs
- Experience